Skip to main content

Table 2 Results of descriptive and psychometric analyses of the EORTC QLQ-PR25 by group

From: Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients

  

Raw responses (n=633)

Rasch analysis

 

EORTC QLQ-PR25 Items ranked by difficulty

Mean score

“Very Much”

“Not at all”

 

T0

T1

T2

Total

DIF (P-value)

     

α

(n=135)

(n=117)

(n=381)

(n=633)

Infit

Targeting

among Groups: T0, T1, T2

  

(SD)

%

%

 

δ

δ

δ

δ

 

(SD)

T0 vs. T1

T0 vs. T2

T1 vs. T2

Urinary symptoms (US) a

   

0.77

     

2.26

   

US37

Painful voiding (least frequent)

3.84(0.39)

0.0

84.5

 

−1.67

−2.05

−2.10

−2.00

1.23

(1.57)

0.257

0.130

0.865

US39

Limitation of activities because of US

3.67(0.62)

1.8

73.5

 

−1.30

−0.85

−0.98

−0.72

1.41

 

0.109

0.185

0.556

US35

Need to remain close to toilet

3.54(0.72)

2.6

64.3

 

−0.57

−0.21

−0.30

−0.37

1.08

 

0.147

0.208

0.633

US36

Urinary incontinence

3.53(0.63)

1.0

59.7

 

−0.91

−0.06

−0.23

−0.35

1.11

 

0.001

0.002

0.389

US34

Sleep deprivation because of US

3.25(0.82)

4.8

44.2

 

0.85

0.63

0.54

0.58

1.03

 

0.291

0.080

0.644

US31

Frequent urination in daytime

3.18(0.79)

3.4

38.7

 

0.87

0.80

0.83

0.78

0.86

 

0.753

0.815

0.884

US33

Urinary urgency

3.15(0.81)

6.1

35.7

 

0.97

0.78

0.94

0.87

0.93

 

0.347

0.845

0.347

US32

Nocturia (most frequent)

3.01(0.81)

5.3

28.1

 

1.49

1.09

1.27

1.22

0.79

 

0.044

0.172

0.278

Bowel symptoms (BS) a

   

0.41

     

3.58

   

BS42

Fecal blood (least frequent)

3.93(0.31)

0.3

93.5

 

−0.74

−0.56

−0.77

−0.71

1.27

(1.03)

0.713

0.954

0.622

BS41

Fecal incontinence

3.92(0.29)

0.0

92.6

 

−0.63

−1.07

−0.47

−0.63

0.98

 

0.384

0.689

0.172

BS40

Limitation of activities because of BS

3.82(0.45)

0.6

84.8

 

0.36

0.95

0.51

0.59

0.98

 

0.101

0.646

0.131

BS43

Bloated feeling (most frequent)

3.80(0.44)

0.5

81.8

 

0.94

0.50

0.74

0.74

0.95

 

0.206

0.490

0.421

Treatment-related symptoms (TS) a

   

0.41

     

3.32

   

TS45

Breast tenderness (least frequent)

3.96(0.20)

0.0

96.0

 

−1.95

−2.69

−1.42

−1.69

0.96

(1.22)

0.407

0.356

0.098

TS44

Hot flushes

3.89(0.34)

0.0

89.9

 

−0.46

−0.41

−0.68

−0.57

0.97

 

0.896

0.514

0.407

TS46

Swelling in legs or ankles

3.84(0.48)

1.0

87.1

 

0.08

0.25

−0.28

−0.09

1.27

 

0.599

0.202

0.048

TS48

Bothered due to weight gain

3.81(0.47)

0.6

83.9

 

−0.07

0.09

0.13

0.09

0.99

 

0.639

0.483

0.883

TS47

Bothered due to weight loss

3.78(0.51)

0.8

81.8

 

0.71

0.47

0.04

0.28

1.05

 

0.394

0.006

0.081

TS49

Felt less masculine (most frequent)

3.31(0.86)

4.9

52.6

 

1.73

1.76

2.11

1.98

0.97

 

0.858

0.033

0.045

Sexual functioning (SX) b

   

0.80

     

−6.41

   

SX50

Sexual interest (more likely)

1.53(0.72)

1.7

58.5

 

−1.11

−1.67

−1.87

−1.67

0.88

(3.97)

0.314

0.072

0.663

SX51

Sexual activity (less likely)

1.34(0.59)

1.1

70.8

 

1.10

1.67

1.89

1.67

0.92

 

0.316

0.068

0.650

  1. Group T0: before therapy; Group T1: one month after the start of therapy; Group T2: therapy for 3 months or more; Group Total: Group T0 + T1 + T2.
  2. a Raw responses: 1: “Very much”; 2: “Quite a bit”; 3: “A little”; 4: “Not at all”, higher score means better HRQOL/less frequent symptom.
  3. b Raw responses: 4: “Very much”; 3: “Quite a bit”; 2: “A little”; 1: “Not at all”, higher score means better HRQOL/more interest/activity.
  4. δ: Item difficulty, higher difficulty means worse HRQOL/more frequent symptom/problem; Targeting: the average person ability level.
  5. α: Cronbach’s α > 0.7, acceptable reliability; Infit statistics > 1.4: item misfit; DIF: differential item functioning.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us